Literature DB >> 15606622

Relevance of ex vivo blood lymphocyte assay for in vivo lymphocyte function.

N W Brattig1, C Timmann, R S Abraha, B Lepping, B Müller-Myhsok, R D Horstmann.   

Abstract

Determinations of in vitro proliferative and secretory activities of peripheral blood cells are used widely for research in clinical immunology but, to our knowledge, have not been evaluated as to their power to reflect in vivo activities quantitatively. Here, we addressed this question by quantitatively correlating the in vitro secretion of interleukin (IL)-5 by peripheral blood cells to the in vivo activity of IL-5 as reflected by peripheral-blood eosinophil counts. Studying 458 humans exposed to transmission of the nematode Onchocerca volvulus, IL-5 was measured in the supernatants of 0.02-ml whole-blood cells cultured in the presence of O. volvulus extract or mitogen. O. volvulus-reactive IL-5 secretion was correlated significantly to blood eosinophilia in a quantitative manner explaining 15.1% (95% CI 8.3-19.9%) of the variability of eosinophil counts. Interestingly, correlations were obtained only if parasite counts were included in the calculation using multiple regression analysis. The results show that in vitro assays of minute amounts of blood lymphocytes may quantitatively reflect activities of the entire lymphocyte population in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15606622      PMCID: PMC1809269          DOI: 10.1111/j.1365-2249.2005.02667.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  26 in total

1.  Eotaxin and RANTES expression by the dermal endothelium is associated with eosinophil infiltration after ivermectin treatment of onchocerciasis.

Authors:  P J Cooper; L A Beck; I Espinel; N M Deyampert; A Hartnell; P J Jose; W Paredes; R H Guderian; T B Nutman
Journal:  Clin Immunol       Date:  2000-04       Impact factor: 3.969

2.  IL-5 production by bone marrow stromal cells: implications for eosinophilia associated with asthma.

Authors:  M B Hogan; D Piktel; K S Landreth
Journal:  J Allergy Clin Immunol       Date:  2000-08       Impact factor: 10.793

Review 3.  Lymphocyte mediators and cellular hypersensitivity.

Authors:  J R David
Journal:  N Engl J Med       Date:  1973-01-18       Impact factor: 91.245

4.  Leucocyte interferon production in immunological deficiency diseases.

Authors:  C G Ray; S D Davis
Journal:  Lancet       Date:  1970-02-07       Impact factor: 79.321

5.  In vitro methods in cell-mediated immunity in man.

Authors:  B R Bloom
Journal:  N Engl J Med       Date:  1971-05-27       Impact factor: 91.245

6.  Correlation between eosinophilia induced by CD4(+) T cells and bronchial hyper-responsiveness.

Authors:  A Nakata; O Kaminuma; K Ogawa; H Fujimura; K Fushimi; H Kikkawa; K Naito; K Ikezawa; R W Egan; A Mori
Journal:  Int Immunol       Date:  2001-03       Impact factor: 4.823

Review 7.  Th2 responses without atopy: immunoregulation in chronic helminth infections and reduced allergic disease.

Authors:  M Yazdanbakhsh; A van den Biggelaar; R M Maizels
Journal:  Trends Immunol       Date:  2001-07       Impact factor: 16.687

8.  Generation of rat eosinophils by recombinant rat interleukin-5 in vitro and in vivo.

Authors:  K Ishihara; I Satoh; S Mue; K Ohuchi
Journal:  Biochim Biophys Acta       Date:  2000-04-15

9.  Onchocerca volvulus-exposed persons fail to produce interferon-gamma in response to O. volvulus antigen but mount proliferative responses with interleukin-5 and IL-13 production that decrease with increasing microfilarial density.

Authors:  Norbert W Brattig; Bianca Lepping; Christian Timmann; Dietrich W Büttner; Yeboah Marfo; Christoph Hamelmann; Rolf D Horstmann
Journal:  J Infect Dis       Date:  2002-03-21       Impact factor: 5.226

10.  Interleukin-5 induces CD34(+) eosinophil progenitor mobilization and eosinophil CCR3 expression in asthma.

Authors:  R G Stirling; E L van Rensen; P J Barnes; K F Chung
Journal:  Am J Respir Crit Care Med       Date:  2001-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.